{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:56:01Z","timestamp":1793973361394,"version":"4.8.0"},"reference-count":66,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:sec id=\"ab-ioi250032-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Steatotic liver disease is a major cause of advanced liver disease and is associated with increased risks of long-term adverse outcomes. However, estimates in steatotic liver disease subtypes according to the revised nomenclature are limited in population-based cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi250032-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the risks of adverse liver outcomes, major adverse cardiovascular events (MACE), and all-cause mortality across steatotic liver disease subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi250032-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>A retrospective cohort study of adults with imaging-confirmed hepatic steatosis receiving outpatient care within the national Veterans Health Administration (2010-2021) was carried out. Data were analyzed from April 2024 to March 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi250032-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Steatotic liver disease subtypes, including metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), or their intersection (MetALD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi250032-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcomes were the incidence of adverse liver outcomes (cirrhosis, decompensation, hepatocellular carcinoma, liver transplant, liver-related death), MACE (myocardial infarction, stroke, heart failure, cardiovascular death), and all-cause mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi250032-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 341\u202f601 adults (mean [SD] age, 59.5 (13.2) years; 227\u202f954 non-Hispanic White [66.7%]; 27\u202f606 female [8.1%]), 264\u202f192 had MASLD (77.3%), 61\u202f070 had MetALD (17.9%), and 16\u202f339 had ALD (4.8%). Over a median (IQR) follow-up of 5.5 (3.0-8.4) years, compared with MASLD, MetALD had a higher incidence of adverse liver outcomes (1.12 vs 0.61 per 100 person-years; hazard ratio [HR], 1.56; 95% CI, 1.50-1.62) and all-cause mortality (2.74 vs 2.60 per 100 person-years; HR, 1.08; 95% CI, 1.05-1.10), but similar incidence of MACE. ALD had a higher incidence of adverse liver outcomes (1.78 vs 0.61 per 100 person-years; HR, 2.33; 95% CI, 2.20-2.47) and all-cause mortality (3.42 vs 2.60 per 100 person-years; HR, 1.42; 95% CI, 1.36-1.48) than MASLD, but similar incidence of MACE. The incidence of adverse liver outcomes per 100 person-years increased 10-fold with a higher degree of fibrosis (Fibrosis-4 score &amp;amp;lt;1.30 vs &amp;amp;gt;2.67) across MASLD (0.28 vs 3.02), MetALD (0.39 vs 4.31), and ALD (0.61 vs 5.05). Severe alcohol use, alcohol use disorder, and diabetes were the factors most strongly associated with adverse liver outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi250032-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This cohort study found that patients with MetALD and ALD had modestly higher risks of adverse liver outcomes and all-cause mortality than those with MASLD, with similar risks of MACE. Alcohol and fibrosis assessments may help identify patients at increased risk for long-term adverse outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamainternmed.2025.1809","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T11:30:57Z","timestamp":1750073457000},"page":"986","source":"Crossref","is-referenced-by-count":55,"title":["Adverse Liver Outcomes, Cardiovascular Events, and Mortality in Steatotic Liver Disease"],"prefix":"10.1001","volume":"185","author":[{"given":"Pedro","family":"Ochoa-Allemant","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Hubbard","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Brown University School of Public Health, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Gastroenterology Section, Department of Medicine, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Serper","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Gastroenterology Section, Department of Medicine, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania"},{"name":"Leonard Davis Institute of Health Economics, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"ioi250032r1","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature.","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"ioi250032r2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement.","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"ioi250032r3","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000324","article-title":"Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States.","volume":"7","author":"Ochoa-Allemant","year":"2023","journal-title":"Hepatol Commun"},{"issue":"5","key":"ioi250032r4","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"8","key":"ioi250032r5","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1053\/j.gastro.2016.03.005","article-title":"Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality.","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"},{"issue":"10","key":"ioi250032r6","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease.","volume":"9","author":"Hagstr\u00f6m","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"ioi250032r7","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.jhep.2023.08.008","article-title":"Progression of nonalcoholic fatty liver disease and long-term outcomes: a nationwide paired liver biopsy cohort study.","volume":"79","author":"Simon","year":"2023","journal-title":"J Hepatol"},{"issue":"5","key":"ioi250032r8","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jhep.2021.12.031","article-title":"Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.","volume":"76","author":"Boursier","year":"2022","journal-title":"J Hepatol"},{"issue":"2","key":"ioi250032r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100915","article-title":"Long-term major adverse liver outcomes in 1,260 patients with non-cirrhotic NAFLD.","volume":"6","author":"Akbari","year":"2023","journal-title":"JHEP Rep"},{"issue":"9","key":"ioi250032r10","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","article-title":"Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort.","volume":"71","author":"Simon","year":"2022","journal-title":"Gut"},{"issue":"3","key":"ioi250032r11","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S2468-1253(23)00443-0","article-title":"Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.","volume":"9","author":"Israelsen","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"ioi250032r12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/apt.18015","article-title":"Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality.","volume":"60","author":"Tamaki","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"ioi250032r13","first-page":"533","article-title":"Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.","volume":"73","author":"Lee","year":"2024","journal-title":"Gut"},{"issue":"5","key":"ioi250032r14","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jhep.2022.07.004","article-title":"Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design.","volume":"77","author":"Allen","year":"2022","journal-title":"J Hepatol"},{"issue":"17","key":"ioi250032r15","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease.","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"ioi250032r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102149","article-title":"Large-scale identification of undiagnosed hepatic steatosis using natural language processing.","volume":"62","author":"Schneider","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"6","key":"ioi250032r24","doi-asserted-by":"publisher","first-page":"751","DOI":"10.7326\/M22-2751","article-title":"Primary occurrence of cardiovascular events after adding sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists compared with dipeptidyl peptidase-4 inhibitors: a cohort study in veterans with diabetes.","volume":"176","author":"Richardson","year":"2023","journal-title":"Ann Intern Med"},{"issue":"7","key":"ioi250032r25","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000468","article-title":"Identification of hepatic steatosis among persons with and without HIV using natural language processing.","volume":"8","author":"Torgersen","year":"2024","journal-title":"Hepatol Commun"},{"issue":"11","key":"ioi250032r26","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1001\/jamainternmed.2024.4661","article-title":"GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease.","volume":"184","author":"Kanwal","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"8","key":"ioi250032r27","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1111\/acer.12092","article-title":"AUDIT-C scores as a scaled marker of mean daily drinking, alcohol use disorder severity, and probability of alcohol dependence in a U.S. general population sample of drinkers.","volume":"37","author":"Rubinsky","year":"2013","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"ioi250032r28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/QAI.0000000000001588","article-title":"Alcohol and mortality: combining self-reported (AUDIT-C) and biomarker detected (PEth) alcohol measures among HIV infected and uninfected.","volume":"77","author":"Eyawo","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"ioi250032r29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jhep.2022.10.022","article-title":"NASH cirrhosis trials and major adverse liver outcomes: big data needed.","volume":"78","author":"Noureddin","year":"2023","journal-title":"J Hepatol"},{"issue":"3","key":"ioi250032r30","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jhep.2022.10.035","article-title":"Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease.","volume":"78","author":"Cholankeril","year":"2023","journal-title":"J Hepatol"},{"issue":"11","key":"ioi250032r31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.43608","article-title":"Risk score for hepatocellular cancer in adults without viral hepatitis or cirrhosis.","volume":"7","author":"Ilagan-Ying","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"ioi250032r32","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.cgh.2019.12.017","article-title":"Identifying patients with hepatic encephalopathy using administrative data in the ICD-10 era.","volume":"19","author":"Tapper","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"13","key":"ioi250032r33","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1016\/j.cgh.2015.07.010","article-title":"Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database.","volume":"13","author":"Kaplan","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"ioi250032r34","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/EDE.0b013e3182821e75","article-title":"Validation of VA administrative data algorithms for identifying cardiovascular disease hospitalization.","volume":"24","author":"Niesner","year":"2013","journal-title":"Epidemiology"},{"key":"ioi250032r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2023.107214","article-title":"Ascertainment of stroke from administrative data to support a pragmatic embedded clinical trial.","volume":"130","author":"Raju","year":"2023","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"ioi250032r36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020455","article-title":"Validation of an algorithm to identify heart failure hospitalisations in patients with diabetes within the veterans health administration.","volume":"8","author":"Presley","year":"2018","journal-title":"BMJ Open"},{"issue":"2","key":"ioi250032r37","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.122.009078","article-title":"Validity of International Classification of Diseases (ICD)-10 diagnosis codes for identification of acute heart failure hospitalization and heart failure with reduced versus preserved ejection fraction in a national Medicare sample.","volume":"16","author":"Bates","year":"2023","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"11","key":"ioi250032r38","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012832","article-title":"Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study.","volume":"6","author":"Sundb\u00f8ll","year":"2016","journal-title":"BMJ Open"},{"issue":"3","key":"ioi250032r39","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2036.2007.03572.x","article-title":"The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases.","volume":"27","author":"Kramer","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"ioi250032r40","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/j.cgh.2018.01.042","article-title":"Positive predictive value of International Classification of Diseases, 10th Revision, codes for cirrhosis and its related complications.","volume":"16","author":"Mapakshi","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"ioi250032r41","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.gastro.2012.03.038","article-title":"The quality of care provided to patients with cirrhosis and ascites in the Department of Veterans Affairs.","volume":"143","author":"Kanwal","year":"2012","journal-title":"Gastroenterology"},{"issue":"4","key":"ioi250032r42","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.cgh.2007.01.014","article-title":"Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival.","volume":"5","author":"Leykum","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"ioi250032r43","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/pds.2148","article-title":"Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study.","volume":"20","author":"Lo Re","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"ioi250032r44","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70024","article-title":"A validated algorithm to identify hepatic decompensation in the Veterans Health Administration Electronic Health Record System.","volume":"33","author":"Haque","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"ioi250032r46","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1093\/ntr\/ntr206","article-title":"Validating smoking data from the Veteran\u2019s Affairs Health Factors dataset, an electronic data source.","volume":"13","author":"McGinnis","year":"2011","journal-title":"Nicotine Tob Res"},{"issue":"6","key":"ioi250032r47","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection.","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"5","key":"ioi250032r48","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis.","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"ioi250032r50","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/1536867X0400400201","article-title":"Cumulative incidence estimation in the presence of competing risks.","volume":"4","author":"Coviello","year":"2004","journal-title":"Stata J"},{"issue":"1","key":"ioi250032r52","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/1536867X1701700110","article-title":"The estimation and modelling of cause-specific cumulative incidence functions using time-dependent weights.","volume":"17","author":"Lambert","year":"2017","journal-title":"Stata J"},{"issue":"6","key":"ioi250032r53","first-page":"1887","article-title":"Robust causal inference using directed acyclic graphs: the R package \u2018dagitty\u2019.","volume":"45","author":"Textor","year":"2016","journal-title":"Int J Epidemiol"},{"issue":"2","key":"ioi250032r54","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000386","article-title":"The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement.","volume":"8","author":"Hagstr\u00f6m","year":"2024","journal-title":"Hepatol Commun"},{"issue":"1","key":"ioi250032r56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacasi.2021.04.007","article-title":"Epidemiological features of cardiovascular disease in Asia.","volume":"1","author":"Zhao","year":"2021","journal-title":"JACC Asia"},{"issue":"1","key":"ioi250032r57","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/apt.18011","article-title":"Steatotic liver disease-associated all-cause\/cause-specific mortality in the United States.","volume":"60","author":"Kim","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"ioi250032r58","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.24495","article-title":"Alcohol consumption patterns and mortality among older adults with health-related or socioeconomic risk factors.","volume":"7","author":"Ortol\u00e1","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"10129","key":"ioi250032r59","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S0140-6736(18)30134-X","article-title":"Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies.","volume":"391","author":"Wood","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"ioi250032r60","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.","volume":"70","author":"Simon","year":"2021","journal-title":"Gut"},{"issue":"5","key":"ioi250032r61","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"5","key":"ioi250032r62","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease.","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"issue":"2","key":"ioi250032r63","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s10620-022-07706-2","article-title":"Primary care providers and nonalcoholic fatty liver disease: a needs assessment survey.","volume":"68","author":"Islam","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"6","key":"ioi250032r64","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis.","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"ioi250032r65","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/HEP.0000000000000545","article-title":"A global action agenda for turning the tide on fatty liver disease.","volume":"79","author":"Lazarus","year":"2024","journal-title":"Hepatology"},{"issue":"11","key":"ioi250032r66","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S2468-1253(24)00220-6","article-title":"Best buy interventions to address the burden of steatotic liver disease.","volume":"9","author":"Lazarus","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ioi250032r49","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"key":"ioi250032r17","unstructured":"U.S. Department of Veterans Affairs. Veterans Health Administration: About VHA. Updated November 8, 2023. Accessed June 20, 2024. https:\/\/www.va.gov\/health\/aboutvha.asp"},{"key":"ioi250032r18","unstructured":"U.S. Department of Veterans Affairs. VA Health Systems Research: Corporate Data Warehouse. Updated November 1, 2023. Accessed June 25, 2024. https:\/\/www.hsrd.research.va.gov\/for_researchers\/cdw.cfm"},{"key":"ioi250032r19","unstructured":"Gidwani? R, Hong? J, Murrell? S. Fee Basis Data: A Guide for Researchers. Health Economics Resource Center, VA Palo Alto Health Care System, U.S. Department of Veterans Affairs. Updated April 3, 2019. Accessed October 27, 2024. https:\/\/www.herc.research.va.gov\/include\/page.asp?id=guidebook-fee-basis"},{"key":"ioi250032r20","unstructured":"Community Care Data - Program Integrity Tool (PIT). Health Economics Resource Center, VA Palo Alto Health Care System, U.S. Department of Veterans Affairs. Updated August, 2023. Accessed October 27, 2024. https:\/\/www.herc.research.va.gov\/include\/page.asp?id=choice-pit"},{"key":"ioi250032r21","unstructured":"Department of Veterans, Office of Mental Health and Suicide Prevention. Joint Department of Veterans Affairs and Department of Defense Mortality Data Repository. Data compiled from the National Death Index. Accessed February 8, 2024. https:\/\/www.mirecc.va.gov\/suicideprevention\/documents\/VA_DoD-MDR_Flyer-92422-update.pdf"},{"key":"ioi250032r22","unstructured":"Centers for Disease Control and Prevention. Prevalence of CKD stages 3-5 by age and race\/ethnicity. National Center for Chronic Disease Prevention and Health Promotion. Accessed June 23, 2024. https:\/\/nccd.cdc.gov\/CKD\/Methods.aspx?QNum=Q373"},{"key":"ioi250032r23","unstructured":"U.S. Department of Veterans Affairs. Veterans Health Administration: Veterans Integrated Services Networks (VISNs). Updated January 29, 2024. Accessed June 25, 2024. https:\/\/www.va.gov\/HEALTH\/visns.asp"},{"key":"ioi250032r45","unstructured":"Social deprivation index (SDI). Robert Graham Center - Policy Studies in Family Medicine & Primary Care. Accessed July 6, 2024. https:\/\/www.graham-center.org\/maps-data-tools\/social-deprivation-index.html"},{"key":"ioi250032r51","unstructured":"STCOMLIST. Stata module to list cumulative function in presence of competing risks. 2017. Accessed February 24, 2025. https:\/\/EconPapers.repec.org\/RePEc:boc:bocode:s458292"},{"key":"ioi250032r55","unstructured":"Substance Abuse and Mental Health Services Administration. Screening, Brief Intervention, and Referral to Treatment (SBIRT). Updated August 2022. Accessed November 14, 2024. https:\/\/www.samhsa.gov\/sbirt"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2835432\/jamainternal_ochoaallemant_2025_oi_250032_1753201851.31902.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T15:01:07Z","timestamp":1754319667000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2835432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":66,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2025.1809","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}